On January 15, 2026, Yaohai Bio-Pharma’s strategic partner, Wuhan Huajiyuan Biotechnology Development Co., Ltd. (Huajiyuan Biotech), announced that its independently developed product, HJY-ATRQβ-001, the world’s
Biologics development faces growing challenges. These include high R&D costs, complex technologies, and long clinical timelines. Companies must balance limited resources with tight schedules. At
Yaohai Bio-Pharma is a leading CRDMO specializing in microbial expression systems. We offer end-to-end purification process development, starting from primary purification and moving all the
Yaohai Bio-Pharma provides integrated, end-to-end microbial fermentation services under the highest global GMP standards. With this combination of technology and experience, we become a reliable
Yaohai Bio-Pharma operates a cutting-edge microbial CRDMO platform built on E. coli and yeast expression systems. In addition, we offer one-stop microbial cell banking solutions
Yaohai Bio-Pharma has more than 15 years of experience in microbial cell line development and cell bank construction. Microbial cell line development and high-yield strain
